COMPASS Trial

Aspiration Thrombectomy vs. Stent Retriever Thrombectomy as First-Line Approach


Note: COMPASS is an independent, physician-initiated study funded with a research grant by Penumbra, Inc. Penumbra did not play a role in the execution, data collection, data analysis, interpretation, or presentation of results of the COMPASS study.
Distal Aspiration Drives Success with ADAPT or Combination Therapy

Favorable Non-Inferior Clinical Outcome

<table>
<thead>
<tr>
<th></th>
<th>ADAPT</th>
<th>SR</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality at 90 days</td>
<td>22.0%</td>
<td>22.0%</td>
<td>1.02 (.57, 1.81)</td>
</tr>
<tr>
<td>sICH (all ICH with NIHSS ≥ 4 worsening)</td>
<td>6%</td>
<td>6%</td>
<td>1.01 (.37, 2.77)</td>
</tr>
</tbody>
</table>

High Revascularization Rates

- ADAPT (121/136) vs. SR (121/136)
  - mRS ≤ 2 at 90 days: 92% vs. 89%, p = .0014
  - TICI 2b/3 (final): 83% vs. 81%, p = .32

First Pass Success

- TICI 2b/3 (primary modality only): 56% vs. 56%, p = .75
- TICI 2c (final): 57% vs. 51%, p = .32

Safety

- Total Procedure Cost (median) for ADAPT: $6,633 vs. SR: $12,790
  - ADAPT p = .0194 vs. SR p < .0001

The opinions and clinical experiences presented herein are for informational purposes only. The results may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors.
Trial Background

Design
- Prospective, randomized, international, multi-center, blinded assessment concurrent controlled trial

Population
- Anterior circulation ELVO (ICA to MCA Bifurcation) within 6 hours of onset

Randomization
- 1:1 ADAPT vs. Stent Retriever Frontline (SRFL)

Assessment
- Blinded core lab adjudication of imaging
- Blinded mRS confirmed clinical assessment

Baseline Characteristics

<table>
<thead>
<tr>
<th></th>
<th>ADAPT (134)</th>
<th>SRFL (136)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>71.8 ± 3.1</td>
<td>71.1 ± 12.9</td>
</tr>
<tr>
<td>Gender (female)</td>
<td>58%</td>
<td>50%</td>
</tr>
<tr>
<td>Baseline NIHSS (median)</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>Baseline ASPECTS Score (median)</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>

Sites
- 6 centers in North America
  - 6 centers with > 67% ADAPT cases
  - 6 centers with > 67% SRFL cases
  - 3 centers with mixed technique
  - 270 patients enrolled

Potential Adverse Events
- Kidney damage from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening, burns, alopecia, or neoplasia from x-ray exposure.